uniQure N.V. announced on January 7, 2025, its commencement of an underwritten public offering of its ordinary shares and pre-funded warrants. All securities in the offering are being sold by uniQure, indicating a direct capital raise for the company.
The company also intends to grant the underwriters a 30-day option to purchase up to 15% additional ordinary shares at the public offering price, less underwriting discounts and commissions. This offering is subject to market and other conditions, with no assurance as to its completion, size, or terms.
This proposed financing event is a strategic move to bolster uniQure's financial position, providing capital to advance its pipeline of gene therapies, including the lead candidate AMT-130 for Huntington's disease, and other programs for refractory temporal lobe epilepsy, ALS, and Fabry disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.